Sativex MS spasticity spray now with CNX Therapeutics after sale
Cannabis-based medication used as add-on therapy in Canada, most of Europe
Sativex (nabiximols) — a cannabis-based oral spray used to ease spasticity in certain people with multiple sclerosis (MS) — has been acquired by CNX Therapeutics, which will now market the therapy in Europe and other international regions.
The therapy, previously developed by Jazz Pharmaceuticals, is approved as an add-on treatment in most of Europe and in Canada. It is not approved in the U.S.
In those regions, Sativex is indicated for adults with moderate to severe MS-related spasticity who have not responded adequately to other anti-spasticity medications and who show clinical benefit during an initial trial period.
Deal expands CNX Therapeutics’ CNS portfolio
The acquisition covers all marketing authorizations, commercial partnerships, and manufacturing and supply operations. It also broadens CNX Therapeutics’ portfolio of treatments for conditions affecting the central nervous system (CNS) — which includes the brain and spinal cord.
“This acquisition strengthens CNX Therapeutics’ position as a provider of specialist CNS medicines across European markets,” Guy Clark, CEO of CNX, said in a company press release.
Clark added Sativex “represents a significant milestone in our strategy to grow through focused acquisitions in therapeutic areas where we can make a meaningful change.”
Jazz Pharmaceuticals will provide transitional support to help ensure a smooth handover. In turn, CNX Therapeutics has pledged to maintain uninterrupted supply and long-term access to the therapy.
“We’re committed to ensuring continuity of supply and support for patients and healthcare professionals for the long term,” Clark said.
Spasticity among most common symptoms of MS
In MS, damage to the nerve cells in the CNS leads to a wide range of symptoms. Spasticity — characterized by muscle stiffness, tightness, and involuntary muscle spasms — is one of the most common, affecting up to 90% of people with MS.
Although several medications are approved to help manage spasticity in those with MS, these can cause side effects that restrict long-term use, may lose effectiveness over time, or fail to provide adequate symptom relief.
As a result, many with MS explore cannabinoid-based therapies — compounds derived from the cannabis plant — to help relieve muscle tension and improve comfort.
Sativex is one such therapy — an oral spray applied under the tongue or inside the cheek several times a day. It is licensed in some countries for use when other treatments are inadequate.
Sativex contains roughly equal amounts of delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main active compounds found in the cannabis plant. By acting on receptors of the body’s endocannabinoid system — which influences muscle tone, movement, and pain signaling — the therapy may help reduce spasms and ease other symptoms of MS spasticity.
“Our established CNS infrastructure and deep therapeutic expertise made this acquisition a strategic fit as we continue building our European specialty portfolio. We’re focused on ensuring seamless continuity of access for patients who rely on this treatment,” said Ben Moore, vice president of corporate development at CNX Therapeutics.
About the Author
